Liver Transplantation News and Research RSS Feed - Liver Transplantation News and Research

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

An experimental nanoparticle therapy that combines low-density lipoproteins (LDL) and fish oil preferentially kills primary liver cancer cells without harming healthy cells, UT Southwestern Medical Center researchers report. [More]
EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Bristol-Myers Squibb today announced that the European Commission has approved the expanded use of Daklinza, a first-in-class oral, once-a-day pill used in combination with other treatments as an option for adult patients with chronic hepatitis C virus infection who are co-infected with HIV or who have had a prior liver transplant. [More]
Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus. [More]
New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

A study by IRB Barcelona and IDIBAPS reveals a therapeutic target to prevent the development of the many abnormal blood vessels that cause gastrointestinal bleeding—the main complication in cirrhosis. [More]
Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

A large multi-center clinical trial has found that a combination of antiviral medications can eradicate hepatitis C infection in more than 90 percent of patients with advanced liver disease. Known as the ASTRAL-4 trial, the study was co-led by investigators at Beth Israel Deaconess Medical Center and Intermountain Medical Center and published online Nov. 17 in The New England Journal of Medicine. [More]
Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Nearly 50 percent of Medicaid patients infected with chronic hepatitis C whose doctors had prescribed newer, life-saving antiviral drugs were denied coverage to the therapies because they weren't considered "a medical necessity" or because the patients tested positive for alcohol/drugs, among other reasons, according to new Penn Medicine research. [More]
Study finds that living liver donors highly satisfied with donation process

Study finds that living liver donors highly satisfied with donation process

A study of living liver donors found donors were highly satisfied with the donation process. Findings published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases, indicate most donors would donate again, independent of any complications from transplantation. [More]
Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis). [More]
SLU hepatologist receives $150,000 grant to study preventative strategies for TPN-associated disorders

SLU hepatologist receives $150,000 grant to study preventative strategies for TPN-associated disorders

When a child is born prematurely, providing nutrition intravenously can be lifesaver. Unfortunately it can also cause liver damage down the road. [More]
Hiroshima University researchers report promising new avenue for treating hepatitis B

Hiroshima University researchers report promising new avenue for treating hepatitis B

A promising new avenue for treating hepatitis B has been reported by researchers at Hiroshima University who have developed a new animal model of the disease. [More]
Surgeons participate in record-setting day of organ transplantation at Baylor University Medical Center

Surgeons participate in record-setting day of organ transplantation at Baylor University Medical Center

One week ago, surgical teams took part in a record-setting day of organ transplantation at Baylor University Medical Center at Dallas. Surgeons on the medical staff performed nine organ transplants on seven patients in one calendar day. [More]
New DNA analysis may guide personalized management of hepatocellular carcinoma

New DNA analysis may guide personalized management of hepatocellular carcinoma

Detection of small fragments of tumor DNA, known as circulating tumor DNA, in a patient's pre-surgery serum samples predicts early recurrence of hepatocellular carcinoma and may guide treatment, according to a study published in Cellular and Molecular Gastroenterology and Hepatology, the basic and translational science journal of the American Gastroenterological Association. [More]
New study of DCD liver transplantations finds no significant link between donor age and organ survival

New study of DCD liver transplantations finds no significant link between donor age and organ survival

Organ donation after circulatory death (DCD), in which transplant organs are taken from donors after ay period of no blood circulation or oxygenation, is often considered inferior to donation after brain death, in which circulation and oxygenation are maintained until organs are removed for transplantation. Currently, the use of livers from DCD donors remains controversial, particularly with donors with advanced age. [More]
MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer. [More]
Transplanting multi-layered sheet of liver cells into damaged liver improves function in test animals

Transplanting multi-layered sheet of liver cells into damaged liver improves function in test animals

Liver transplantation is currently the only established treatment for patients with end stage liver failure. However, this treatment is limited by the shortage of donors and the conditional integrity and suitability of the available organs. Transplanting donor hepatocytes (liver cells) into the liver as an alternative to liver transplantation also has drawbacks as the rate of survival of primary hepatocytes is limited and often severe complications can result from the transplantation procedure. [More]
Yale study identifies new barrier to caring for chronic hepatitis C patients

Yale study identifies new barrier to caring for chronic hepatitis C patients

Nearly one in four patients with chronic hepatitis C (HCV) are denied initial approval for a drug therapy that treats the most common strain of the infection, according to a Yale School of Medicine study. [More]

Breath test for liver disease detection moves closer

Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS. [More]
Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02. [More]
Researchers at Sydney’s Centenary Institute fight against hepatitis infection

Researchers at Sydney’s Centenary Institute fight against hepatitis infection

Today is World Hepatitis Day. 400 million people around the world are currently living with hepatitis B or C. Each year, we see around 1.4 million people die from viral hepatitis. Researchers at Sydney’s Centenary Institute are working hard to change this. [More]
Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

Approximately 30,000-40,000 people die from liver disease each year, according to the American Liver Foundation. For people who experience acute liver failure, the only proven treatment has been liver transplantation. Researchers at Mayo Clinic have developed and are testing an alternative to liver transplantation called the Spheroid Reservoir Bioartificial Liver that can support healing and regeneration of the injured liver, and improve outcomes and reduce mortality rates for patients with acute liver failure — without requiring a transplant. [More]
Advertisement
Advertisement